For over a decade, medical institutions and activist groups have promoted puberty blockers, cross-sex hormones, and “gender transition” surgeries as necessary, even “life-saving,” treatments for children experiencing gender dysphoria. These procedures were often described as reversible, safe, and supported by evidence.
They lied.
Puberty blockers, once marketed as a harmless “pause button,” are now associated with reduced bone density, impaired brain development, and mental health issues. Cross-sex hormones can cause permanent sterilization, cardiovascular risks, and lasting changes to the body. In addition to that, oftentimes experimental surgical procedures are performed on children, with emerging reports suggesting that a significant number of them later regret it.
The FTC is now reviewing whether institutions deliberately downplayed these risks and exaggerated the benefits of the experimental nature of these “treatments.” In particular, it is examining whether emotionally charged language, such as claims that not pursuing medical intervention leads to suicide, was used to pressure parents into consenting to procedures without fully understanding the consequences.
Financial factors are also being scrutinized. Many of the doctors and clinics advocating for gender-affirming care are directly involved in providing the procedures and prescriptions themselves. Conflicts of interest and financial incentives contributed to the normalization of these corrupt and evil practices.
>>> Submit a Comment Today <<<